Harbin Medical University Cancer Hospital — Harbin, Heilongjiang

Public research footprint of Harbin Medical University Cancer Hospital, compiled from the ClinicalTrials.gov public registry.

571

Registered studies

325

Active

188

Recruiting now

142

Completed

Stopped or withdrawn

Most-studied conditions

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · Carcinoma, Non-Small-Cell Lung · Hepatocellular Carcinoma

Recently updated registry entries

NCT06644781 — A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic… (Recruiting)
NCT07217301 — A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer (Recruiting)
NCT06305754 — Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Harbin Medical University Cancer Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.